Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + pazopanib
- Development stage
- Unknown
- Lead developer
- Unicancer
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination of cisplatin, a platinum-based chemotherapy agent, and pazopanib, a multi-tyrosine kinase inhibitor. This combination has been studied in clinical trials for patients with advanced solid tumors. The maximum tolerated dose was determined to be 400 mg of pazopanib and 75 mg/m² of cisplatin. However, significant pharmacokinetic interactions were observed, with pazopanib metabolism being affected by the cisplatin regimen, likely due to competitive inhibition by aprepitant, an antiemetic drug administered with cisplatin.
02
Targets
PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)CSF1R (Macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on cisplatin + pazopanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + pazopanib.